ClinicalTrials.gov
public full text
Public Domain
RIVastigmine In Vascular cognitivE Impairment
The study is a 24-week prospective, double blind, randomized, placebo-controlled pilot study of 9 mg / day Rivastigmine in patients with Vascular Cognitive Impairment Not Dementia (CIND) to evaluate efficacy, safety and tolerability in Asian patients. The hypothesis is that patients receiving Rivastigmine would improve in executive functioning domains.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Effects of NAD(+) supplementation with oral nicotinamide riboside on vascular health and cognitive function in older adults with peripheral artery disease: Results from a pilot 4-week open-label clinical trial.#123114
- Pioglitazone Or Exercise to Treat Mild Cognitive Impairment (MCI)#1057289
- Clinical trials in vascular cognitive impairment following SPRINT-MIND: An international perspective#491980
- Efficiency of CogniPlat on Cognitive Functions in Older Adults#833939
- Evaluation and Intervention of Cognitive Function in Patients With Diabetes Mellitus.#346900
Record · ID 1114254
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive